Treating uncomplicated malaria with Eurartesim ® (dihydroartemisinin-piperaquine)

If left untreated, a bout of uncomplicated malaria can quickly evolve into severe malaria, which may have life-threatening consequences. Timely access to the appropriate treatment for uncomplicated malaria is key to avoiding this scenario.

Eurartesim is a fixed-dose combination of dihydroartemisinin-piperaquine (DHA-PQP), developed by Alfasigma S.p.A. in partnership with MMV, for the treatment of acute uncomplicated P. falciparum malaria. Studies have also shown that DHA-PPQ’s long half-life affords patients a useful period of protection from new malaria infections.1 2

An essential medicine recommended by WHO  

Eurartesim obtained marketing authorization from the European Medicines Agency (EMA) in 2011 and in 2015, the medicine was prequalified by WHO. In June 2017, Eurartesim was added to WHO’s Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) after a successful application by Alfasigma. 

Increasing access to Eurartesim 

In 2015, Alfasigma entered into an exclusive licensing agreement with Pierre Fabre to expand its ability to support country registration requirements and national adoption of Eurartesim in 32 African countries. To date, over 4.5 million treatments of Eurartesim have been distributed since approval by the EMA. 

Alfasigma will submit a regulatory dossier to the EMA for a new dispersible formulation of Eurartesim designed specifically to address the treatment needs of children. 

→Take a look at the interactive map to see where Eurartesim is registered. 

  • Past and current partners:

    Alfasigma S.p.A, INDEPTH Effectiveness and Safety Studies (INESS), Malaria Control and Elimination Partnership in Africa (MACEPA), Liverpool School of Tropical Medicine, Ministry of Health Cambodia (National Center for Malaria Control, Parasitology and Entomology – CNM; and the Department of Drugs and Food – DDF), Pierre Fabre, Population Services International (Cambodia and Kenya), The Global Fund to Fight AIDS Tuberculosis and Malaria, World Health Organization (Geneva and Cambodia), IsGlobal and The London School of Hygiene and Tropical Medicine.

    1. Valecha Net et al., An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One. 5(7):e11880 (2010)

    2. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al.  Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE 4(11): e7871 (2009). doi: 10.1371/journal.pone.0007871.


    Updated December 2021